New treatment for retinoblastoma in young children
Retinoblastoma Phase II Expanded Access Clinical Trial
['FUNDING_R01'] · TARGETED THERAPY TECHNOLOGIES, LLC · NIH-11105727
This study is testing a new way to treat retinoblastoma, a rare eye cancer in babies and young kids, by using a special device to deliver a chemotherapy drug right to the eye, which could help keep the cancer away without needing more intense treatments like surgery or radiation.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | TARGETED THERAPY TECHNOLOGIES, LLC (nih funded) |
| Locations | 1 site (SOMERSET, UNITED STATES) |
| Trial ID | NIH-11105727 on ClinicalTrials.gov |
What this research studies
This research focuses on a novel treatment for retinoblastoma, a rare eye cancer affecting infants and young children. The approach involves using a specially designed Chemoplaque to deliver the chemotherapy drug Topotecan directly to the eye, minimizing systemic exposure and potential side effects. The trial aims to evaluate the effectiveness of this treatment in achieving sustained cancer remission without the need for more invasive standard care options, such as eye removal or radiation therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are infants and young children diagnosed with retinoblastoma who have not responded to standard treatments.
Not a fit: Patients with retinoblastoma who are not eligible for the trial due to age or those who have already undergone extensive treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective treatment option for children with retinoblastoma, potentially preserving their vision and reducing the risk of long-term complications.
How similar studies have performed: Previous research has shown promising results with similar localized chemotherapy delivery methods, indicating potential for success in this novel approach.
Where this research is happening
SOMERSET, UNITED STATES
- TARGETED THERAPY TECHNOLOGIES, LLC — SOMERSET, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CARVALHO, RICARDO A — TARGETED THERAPY TECHNOLOGIES, LLC
- Study coordinator: CARVALHO, RICARDO A
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.